{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:59:39Z","timestamp":1790683179612,"version":"4.1.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40272-026-00767-0","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:24:49Z","timestamp":1790072689000},"page":"487-504","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current Management and Emerging Therapies for Pediatric Vitiligo: A Narrative Review"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6787-7804","authenticated-orcid":false,"given":"Jade","family":"Howard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Fitzmaurice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2020-7084","authenticated-orcid":false,"given":"Aleena","family":"Boby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4274-7597","authenticated-orcid":false,"given":"Nanette","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"issue":"4","key":"767_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/jamadermatol.2024.0021","volume":"160","author":"Y Renert-Yuval","year":"2024","unstructured":"Renert-Yuval Y, Ezzedine K, Grimes P, Rosmarin D, Eichenfield LF, Castelo-Soccio L, et al. Expert recommendations on use of topical therapeutics for vitiligo in pediatric, adolescent, and young adult patients. JAMA Dermatol. 2024;160(4):453\u201361. https:\/\/doi.org\/10.1001\/jamadermatol.2024.0021.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"767_CR2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-4126","volume":"138","author":"K Ezzedine","year":"2016","unstructured":"Ezzedine K, Silverberg N. A practical approach to the diagnosis and treatment of vitiligo in children. Pediatrics. 2016;138(1):e20154126. https:\/\/doi.org\/10.1542\/peds.2015-4126.","journal-title":"Pediatrics"},{"issue":"3","key":"767_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/ijd.13425","volume":"56","author":"B Solak","year":"2017","unstructured":"Solak B, Dikicier BS, Cosansu NC, Erdem T. Effects of age of onset on disease characteristics in non-segmental vitiligo. Int J Dermatol. 2017;56(3):341\u20135. https:\/\/doi.org\/10.1111\/ijd.13425.","journal-title":"Int J Dermatol"},{"issue":"2","key":"767_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1001\/jamadermatol.2013.927","volume":"149","author":"JI Silverberg","year":"2013","unstructured":"Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life impairment. JAMA Dermatol. 2013;149(2):159\u201364. https:\/\/doi.org\/10.1001\/jamadermatol.2013.927.","journal-title":"JAMA Dermatol"},{"issue":"9988","key":"767_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","volume":"386","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(14)60763-7.","journal-title":"Lancet"},{"issue":"11","key":"767_CR6","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/ng.3680","volume":"48","author":"Y Jin","year":"2016","unstructured":"Jin Y, Andersen G, Yorgov D, Ferrara TM, Ben S, Brownson KM, et al. Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. Nat Genet. 2016;48(11):1418\u201324. https:\/\/doi.org\/10.1038\/ng.3680.","journal-title":"Nat Genet"},{"key":"767_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-97296-2","volume":"11","author":"F Lin","year":"2021","unstructured":"Lin F, Hu W, Xu W, et al. CXCL9 as a key biomarker of vitiligo activity and prediction of the success of cultured melanocyte transplantation. Sci Rep. 2021;11:18298. https:\/\/doi.org\/10.1038\/s41598-021-97296-2.","journal-title":"Sci Rep"},{"issue":"4","key":"767_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202250281","volume":"54","author":"H Liu","year":"2024","unstructured":"Liu H, Wang Y, Le Q, Tong J, Wang H. The IFN-\u03b3-CXCL9\/CXCL10-CXCR3 axis in vitiligo: pathological mechanism and treatment. Eur J Immunol. 2024;54(4):e2250281. https:\/\/doi.org\/10.1002\/eji.202250281.","journal-title":"Eur J Immunol"},{"issue":"2","key":"767_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.pcl.2013.11.008","volume":"61","author":"NB Silverberg","year":"2014","unstructured":"Silverberg NB. Pediatric vitiligo. Pediatr Clin North Am. 2014;61(2):347\u201366. https:\/\/doi.org\/10.1016\/j.pcl.2013.11.008.","journal-title":"Pediatr Clin North Am"},{"issue":"4","key":"767_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1521\/bumc.2024.88.4.297","volume":"88","author":"Z Siddiqui","year":"2024","unstructured":"Siddiqui Z, Felder E, Hernandez K, Loike-Weinstein D, Waseem M. The psychosocial impact of pediatric vitiligo, psoriasis, eczema, and alopecia: A systematic review. Bull Menninger Clin. 2024;88(4):297\u2013319. https:\/\/doi.org\/10.1521\/bumc.2024.88.4.297.","journal-title":"Bull Menninger Clin"},{"issue":"3","key":"767_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/pde.12226","volume":"31","author":"JI Silverberg","year":"2014","unstructured":"Silverberg JI, Silverberg NB. Quality of life impairment in children and adolescents with vitiligo. Pediatr Dermatol. 2014;31(3):309\u201318. https:\/\/doi.org\/10.1111\/pde.12226.","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"767_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40272-015-0135-3","volume":"17","author":"F Van Driessche","year":"2015","unstructured":"Van Driessche F, Silverberg N. Current management of pediatric vitiligo. Paediatr Drugs. 2015;17(4):303\u201313. https:\/\/doi.org\/10.1007\/s40272-015-0135-3.","journal-title":"Paediatr Drugs"},{"issue":"4","key":"767_CR13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000350337","volume":"18","author":"E Fleissig","year":"2013","unstructured":"Fleissig E, Gross M, Ophir I, Elidan J, Bdolah-Abram T, Ingber A. Risk of sensorineural hearing loss in patients with vitiligo. Audiol Neurootol. 2013;18(4):240\u20136. https:\/\/doi.org\/10.1159\/000350337.","journal-title":"Audiol Neurootol"},{"issue":"1","key":"767_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s41687-020-0186-2","volume":"4","author":"G Andrade","year":"2020","unstructured":"Andrade G, Rangu S, Provini L, Putterman E, Gauthier A, Castelo-Soccio L. Childhood vitiligo impacts emotional health of parents: a prospective, cross-sectional study of quality of life for primary caregivers. J Patient Rep Outcomes. 2020;4(1):20. https:\/\/doi.org\/10.1186\/s41687-020-0186-2.","journal-title":"J Patient Rep Outcomes"},{"issue":"6","key":"767_CR15","first-page":"385","volume":"98","author":"T Chen","year":"2016","unstructured":"Chen T, Grau C, Suprun M, Silverberg NB. Vitiligo patients experience barriers in accessing care. Cutis. 2016;98(6):385\u20138.","journal-title":"Cutis"},{"issue":"2","key":"767_CR16","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.36849\/JDD.7572","volume":"23","author":"M Weingarten","year":"2024","unstructured":"Weingarten M, Schwartz M, Heath C, Silverberg NB. The pediatric dermatologist\u2019s view of pediatric vitiligo. J Drugs Dermatol. 2024;23(2):e77\u20138. https:\/\/doi.org\/10.36849\/JDD.7572.","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"767_CR17","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1111\/jdv.19451","volume":"37","author":"N van Geel","year":"2023","unstructured":"van Geel N, Speeckaert R, Ta\u00efeb A, Ezzedine K, Lim HW, Pandya AG, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm. J Eur Acad Dermatol Venereol. 2023;37(11):2173\u201384. https:\/\/doi.org\/10.1111\/jdv.19451. (Epub 2023 Sep 25).","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"767_CR18","first-page":"463","volume":"81","author":"OE Pagovich","year":"2008","unstructured":"Pagovich OE, Silverberg JI, Freilich E, Silverberg NB. Thyroid abnormalities in pediatric patients with vitiligo in New York City. Cutis. 2008;81(6):463\u20136.","journal-title":"Cutis"},{"issue":"Suppl 2","key":"767_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/pde.14775","volume":"38","author":"R Trachtman","year":"2021","unstructured":"Trachtman R, Silverberg NB. Review article: emerging issues in pediatric skin of color, part 1. Pediatr Dermatol. 2021;38(Suppl 2):20\u20139. https:\/\/doi.org\/10.1111\/pde.14775.","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"767_CR20","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.jaad.2013.04.050","volume":"69","author":"JI Silverberg","year":"2013","unstructured":"Silverberg JI, Silverberg NB. Clinical features of vitiligo associated with comorbid autoimmune disease: a prospective survey. J Am Acad Dermatol. 2013;69(5):824\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2013.04.050.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"767_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jamadermatol.2019.4483","volume":"156","author":"L Zhang","year":"2020","unstructured":"Zhang L, Chen S, Kang Y, et al. Association of clinical markers with disease progression in patients with vitiligo from China. JAMA Dermatol. 2020;156(3):288\u201395. https:\/\/doi.org\/10.1001\/jamadermatol.2019.4483.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"767_CR22","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.jid.2020.12.028","volume":"141","author":"J Seneschal","year":"2021","unstructured":"Seneschal J, Duplaine A, Maillard H, Taieb A, Jouary T, Boniface K, et al. Efficacy and safety of tacrolimus 0.1% for the treatment of facial vitiligo: a multicenter randomized, double-blinded, Vehicle-Controlled Study. J Investig Dermatol. 2021;141(7):1728\u201334. https:\/\/doi.org\/10.1016\/j.jid.2020.12.028.","journal-title":"J Investig Dermatol"},{"issue":"5","key":"767_CR23","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jaad.2004.05.036","volume":"51","author":"NB Silverberg","year":"2004","unstructured":"Silverberg NB, Lin P, Travis L, Farley-Li J, Mancini AJ, Wagner AM, et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol. 2004;51(5):760\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2004.05.036.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"767_CR24","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1111\/jdv.19450","volume":"37","author":"J Seneschal","year":"2023","unstructured":"Seneschal J, Speeckaert R, Ta\u00efeb A, Wolkerstorfer A, Passeron T, Pandya AG, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international Vitiligo Task Force-Part 2: specific treatment recommendations. J Eur Acad Dermatol Venereol. 2023;37(11):2185\u201395. https:\/\/doi.org\/10.1111\/jdv.19450.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"767_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S2352-4642(22)00283-8","volume":"7","author":"N Devasenapathy","year":"2023","unstructured":"Devasenapathy N, Chu A, Wong M, et al. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2023;7(1):13\u201325. https:\/\/doi.org\/10.1016\/S2352-4642(22)00283-8.","journal-title":"Lancet Child Adolesc Health"},{"issue":"8","key":"767_CR26","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/jamadermatol.2019.0696","volume":"155","author":"JH Lee","year":"2019","unstructured":"Lee JH, Kwon HS, Jung HM, et al. Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(8):929\u201338. https:\/\/doi.org\/10.1001\/jamadermatol.2019.0696.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"767_CR27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaad.2015.04.008","volume":"73","author":"JM Bae","year":"2015","unstructured":"Bae JM, Yoo HJ, Kim H, Lee JH, Kim GM. Combination therapy with 308-nm excimer laser, topical tacrolimus, and short-term systemic corticosteroids for segmental vitiligo: a retrospective study of 159 patients. J Am Acad Dermatol. 2015;73(1):76\u201382. https:\/\/doi.org\/10.1016\/j.jaad.2015.04.008.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"767_CR28","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1111\/pde.13726","volume":"36","author":"L Li","year":"2019","unstructured":"Li L, Liang Y, Hong J, Lan L, Xiao H, Xie Z. The effectiveness of topical therapy combined with 308-nm excimer laser on vitiligo compared to excimer laser monotherapy in pediatric patients. Pediatr Dermatol. 2019;36(1):e53\u20135. https:\/\/doi.org\/10.1111\/pde.13726.","journal-title":"Pediatr Dermatol"},{"issue":"7","key":"767_CR29","doi-asserted-by":"publisher","first-page":"773","DOI":"10.36849\/JDD.6895","volume":"21","author":"S Sethi","year":"2022","unstructured":"Sethi S, Silverberg N. Short and long-term outcomes of 308-nm laser for pediatric vitiligo. J Drugs Dermatol. 2022;21(7):773\u20135. https:\/\/doi.org\/10.36849\/JDD.6895.","journal-title":"J Drugs Dermatol"},{"issue":"16","key":"767_CR30","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin D, Passeron T, Pandya AG, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387(16):1445\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2118828.","journal-title":"N Engl J Med"},{"issue":"6","key":"767_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.404","volume":"4","author":"JE Harris","year":"2024","unstructured":"Harris JE, Pandya AG, Lebwohl M, Hamzavi IH, Grimes P, Gottlieb AB, et al. Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: a randomised controlled trial secondary analysis at 3 years. Skin Health Dis. 2024;4(6):e404. https:\/\/doi.org\/10.1002\/ski2.404.","journal-title":"Skin Health Dis."},{"issue":"6","key":"767_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2023.100230","volume":"3","author":"MD Howell","year":"2023","unstructured":"Howell MD, Kuo FI, Rumberger B, Boarder E, Sun K, Butler K, et al. Baseline levels of circulating inflammatory biomarkers stratify patients with vitiligo who significantly repigment after treatment with ruxolitinib cream. JID Innov. 2023;3(6):100230. https:\/\/doi.org\/10.1016\/j.xjidi.2023.100230.","journal-title":"JID Innov"},{"key":"767_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jdcr.2024.02.034","volume":"54","author":"HM Meister","year":"2024","unstructured":"Meister HM, Lebwohl M, Silverberg N. Case series of topical 1.5% ruxolitinib cream for pediatric vitiligo. JAAD Case Rep. 2024;54:27\u201330. https:\/\/doi.org\/10.1016\/j.jdcr.2024.02.034.","journal-title":"JAAD Case Rep"},{"issue":"12","key":"767_CR34","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1111\/ijd.17973","volume":"64","author":"Z Qi","year":"2025","unstructured":"Qi Z, Zhang L, Chang S, Guo S, Zhang Y, Jiang G. 308\u2009nm excimer laser combined with JAK inhibitors for adult localized non-segmental vitiligo: a multicenter randomized controlled trial. Int J Dermatol. 2025;64(12):2283\u201391. https:\/\/doi.org\/10.1111\/ijd.17973.","journal-title":"Int J Dermatol"},{"issue":"6","key":"767_CR35","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/bjd\/ljaf306","volume":"193","author":"H Mehta","year":"2025","unstructured":"Mehta H, Bishnoi A, Vinay K, Kumaran MS, Parsad D. Comparative efficacy of topical tofacitinib versus topical tacrolimus in the treatment of localized vitiligo: a randomized investigator-blinded intraindividual trial. Br J Dermatol. 2025;193(6):1112\u20139. https:\/\/doi.org\/10.1093\/bjd\/ljaf306.","journal-title":"Br J Dermatol"},{"issue":"7","key":"767_CR36","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/ijd.15464","volume":"60","author":"S Chavez-Alvarez","year":"2021","unstructured":"Chavez-Alvarez S, Herz-Ruelas ME, Raygoza-Cortez AK, Ocampo-Candiani J, Villarreal-Martinez A. Oral mini-pulse therapy with betamethasone in vitiligo: a systematic review. Int J Dermatol. 2021;60(7):868\u201376. https:\/\/doi.org\/10.1111\/ijd.15464.","journal-title":"Int J Dermatol"},{"issue":"3","key":"767_CR37","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000433424","volume":"231","author":"H Singh","year":"2015","unstructured":"Singh H, Kumaran MS, Bains A, Parsad D. A randomized comparative study of oral corticosteroid minipulse and low-dose oral methotrexate in the treatment of unstable vitiligo patients having extensive or fast-spreading disease. Dermatology. 2015;231(3):286\u201390. https:\/\/doi.org\/10.1159\/000433424.","journal-title":"Dermatology"},{"issue":"2","key":"767_CR38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4103\/0019-5154.108040","volume":"58","author":"I Majid","year":"2013","unstructured":"Majid I, Imran S. Relapse after methylprednisolone oral minipulse therapy in childhood vitiligo: a 12-month follow-up study. Indian J Dermatol. 2013;58(2):113\u20136. https:\/\/doi.org\/10.4103\/0019-5154.108040.","journal-title":"Indian J Dermatol"},{"issue":"7","key":"767_CR39","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/1346-8138.15858","volume":"48","author":"M Wada-Irimada","year":"2021","unstructured":"Wada-Irimada M, Tsuchiyama K, Sasaki R, et al. Efficacy and safety of i.v. methylprednisolone pulse therapy for vitiligo: a retrospective study of 58 therapy experiences for 33 vitiligo patients. J Dermatol. 2021;48(7):1090\u20133. https:\/\/doi.org\/10.1111\/1346-8138.15858.","journal-title":"J Dermatol"},{"issue":"10","key":"767_CR40","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1365-4362.1993.tb02754.x","volume":"32","author":"JS Pasricha","year":"1993","unstructured":"Pasricha JS, Khaitan BK. Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. Int J Dermatol. 1993;32(10):753\u20137. https:\/\/doi.org\/10.1111\/j.1365-4362.1993.tb02754.x.","journal-title":"Int J Dermatol"},{"issue":"4","key":"767_CR41","doi-asserted-by":"publisher","first-page":"357","DOI":"10.4103\/0378-6323.42905","volume":"74","author":"N Rath","year":"2008","unstructured":"Rath N, Kar HK, Sabhnani S. An open labeled, comparative clinical study on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad \/ narrow band UVB phototherapy in progressive vitiligo. Indian J Dermatol Venereol Leprol. 2008;74(4):357\u201360. https:\/\/doi.org\/10.4103\/0378-6323.42905.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"767_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2310\/7750.2013.12053","volume":"17","author":"AJ Kanwar","year":"2013","unstructured":"Kanwar AJ, Mahajan R, Parsad D. Low-dose oral mini-pulse dexamethasone therapy in progressive unstable vitiligo. J Cutan Med Surg. 2013;17(4):259\u201368. https:\/\/doi.org\/10.2310\/7750.2013.12053.","journal-title":"J Cutan Med Surg"},{"issue":"7","key":"767_CR43","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamadermatol.2017.0002","volume":"153","author":"JM Bae","year":"2017","unstructured":"Bae JM, Jung HM, Hong BY, et al. Phototherapy for vitiligo: a systematic review and meta-analysis. JAMA Dermatol. 2017;153(7):666\u201374. https:\/\/doi.org\/10.1001\/jamadermatol.2017.0002.","journal-title":"JAMA Dermatol"},{"issue":"2 Pt 1","key":"767_CR44","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0190-9622(00)90133-6","volume":"42","author":"MD Njoo","year":"2000","unstructured":"Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol. 2000;42(2 Pt 1):245\u201353. https:\/\/doi.org\/10.1016\/S0190-9622(00)90133-6.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"767_CR45","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaad.2023.02.010","volume":"89","author":"AC Garza-Mayers","year":"2023","unstructured":"Garza-Mayers AC, Paquette GM, Harris JE, Wiss K. Narrowband ultraviolet B phototherapy in pediatric vitiligo: a retrospective study. J Am Acad Dermatol. 2023;89(1):135\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2023.02.010.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"767_CR46","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3906\/sag-1512-59","volume":"47","author":"S Yazici","year":"2017","unstructured":"Yazici S, G\u00fcnay B, Ba\u015fkan EB, Aydo\u011fan K, Saricao\u011flu H, Tunali \u015e. The efficacy of narrowband UVB treatment in pediatric vitiligo: a retrospective analysis of 26 cases. Turk J Med Sci. 2017;47(2):381\u20134. https:\/\/doi.org\/10.3906\/sag-1512-59.","journal-title":"Turk J Med Sci."},{"issue":"4","key":"767_CR47","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/phpp.12462","volume":"35","author":"L Zhang","year":"2019","unstructured":"Zhang L, Wang X, Chen S, et al. Comparison of efficacy and safety profile for home NB-UVB vs. outpatient NB-UVB in the treatment of non-segmental vitiligo: a prospective cohort study. Photodermatol Photoimmunol Photomed. 2019;35(4):261\u20137. https:\/\/doi.org\/10.1111\/phpp.12462.","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"5","key":"767_CR48","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamadermatol.2020.0218","volume":"156","author":"JM Bae","year":"2020","unstructured":"Bae JM, Ju HJ, Lee RW, et al. Evaluation for skin cancer and precancer in patients with vitiligo treated with long-term narrowband UV-B phototherapy. JAMA Dermatol. 2020;156(5):529\u201337. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0218.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"767_CR49","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/archderm.140.6.677","volume":"140","author":"I Hamzavi","year":"2004","unstructured":"Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol. 2004;140(6):677\u201383. https:\/\/doi.org\/10.1001\/archderm.140.6.677.","journal-title":"Arch Dermatol"},{"issue":"9","key":"767_CR50","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1111\/j.1365-4632.2011.05454.x","volume":"51","author":"R Sapam","year":"2012","unstructured":"Sapam R, Agrawal S, Dhali TK. Systemic PUVA vs. narrowband UVB in the treatment of vitiligo: a randomized controlled study. Int J Dermatol. 2012;51(9):1107\u201315. https:\/\/doi.org\/10.1111\/j.1365-4632.2011.05454.x.","journal-title":"Int J Dermatol"},{"issue":"5","key":"767_CR51","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/j.1468-3083.2006.02035.x","volume":"21","author":"A Bhatnagar","year":"2007","unstructured":"Bhatnagar A, Kanwar AJ, Parsad D, De D. Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study. J Eur Acad Dermatol Venereol. 2007;21(5):638\u201342. https:\/\/doi.org\/10.1111\/j.1468-3083.2006.02035.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"767_CR52","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1046\/j.1523-1747.2003.12350.x","volume":"121","author":"TE Nijsten","year":"2003","unstructured":"Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen ultraviolet A: a cohort study. J Invest Dermatol. 2003;121:252\u20138.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"767_CR53","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1111\/ijd.17157","volume":"63","author":"A Utama","year":"2024","unstructured":"Utama A, Wijesinghe R, Thng S. Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review. Int J Dermatol. 2024;63(8):1020\u201335. https:\/\/doi.org\/10.1111\/ijd.17157.","journal-title":"Int J Dermatol"},{"issue":"4","key":"767_CR54","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736\u201344. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.005.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"767_CR55","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/acr.25465","volume":"77","author":"HI Brunner","year":"2025","unstructured":"Brunner HI, Shmagel A, Horneff G, et al. Pharmacokinetics, efficacy, and safety of upadacitinib in pediatric patients with polyarticular-course juvenile idiopathic arthritis: an interim analysis of an open-label, phase 1 trial. Arthritis Care Res (Hoboken). 2025;77(5):584\u201393. https:\/\/doi.org\/10.1002\/acr.25465.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"767_CR56","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/09546634.2020.1735615","volume":"33","author":"K Phan","year":"2022","unstructured":"Phan K, Phan S, Shumack S, Gupta M. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and meta-analysis. J Dermatol Treat. 2022;33(1):173\u20137. https:\/\/doi.org\/10.1080\/09546634.2020.1735615.","journal-title":"J Dermatol Treat"},{"key":"767_CR57","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jdcr.2024.01.033","volume":"46","author":"J Magdaleno-Tapial","year":"2024","unstructured":"Magdaleno-Tapial J, Hern\u00e1ndez-Bel P, Esteve-Mart\u00ednez A, Pe\u00f1uelas-Leal R, Labrandero-Hoyos C, S\u00e1nchez-Carazo JL, et al. Upadacitinib and its role in the treatment of vitiligo: a new possible therapeutic perspective. JAAD Case Rep. 2024;46:57\u20138. https:\/\/doi.org\/10.1016\/j.jdcr.2024.01.033.","journal-title":"JAAD Case Rep"},{"key":"767_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102655","volume":"73","author":"T Passeron","year":"2024","unstructured":"Passeron T, Ezzedine K, Hamzavi I, van Geel N, Schlosser BJ, Wu X, et al. Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study. EClinicalMedicine. 2024;73:102655. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102655.","journal-title":"EClinicalMedicine"},{"key":"767_CR59","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.2147\/CCID.S467026","volume":"17","author":"Y Mu","year":"2024","unstructured":"Mu Y, Pan T, Chen L. Treatment of refractory segmental vitiligo and alopecia areata in a child with upadacitinib and NB-UVB: a case report. Clin Cosmet Investig Dermatol. 2024;17:1789\u201392. https:\/\/doi.org\/10.2147\/CCID.S467026.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"6","key":"767_CR60","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/jdv.20526","volume":"39","author":"C Tziotzios","year":"2025","unstructured":"Tziotzios C, Sinclair R, Lesiak A, et al. Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: results from the ALLEGRO-LT phase 3, open-label study. J Eur Acad Dermatol Venereol. 2025;39(6):1152\u201362. https:\/\/doi.org\/10.1111\/jdv.20526.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"767_CR61","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","volume":"88","author":"K Ezzedine","year":"2023","unstructured":"Ezzedine K, Peeva E, Yamaguchi Y, et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial. J Am Acad Dermatol. 2023;88(2):395\u2013403. https:\/\/doi.org\/10.1016\/j.jaad.2022.11.005.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"767_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03182-y","volume":"316","author":"Y Yamaguchi","year":"2024","unstructured":"Yamaguchi Y, Peeva E, Duca ED, Facheris P, Bar J, Shore R, et al. Ritlecitinib, a JAK3\/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligo. Arch Dermatol Res. 2024;316(7):478. https:\/\/doi.org\/10.1007\/s00403-024-03182-y.","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"767_CR63","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.jaad.2024.11.064","volume":"92","author":"Y Yamaguchi","year":"2025","unstructured":"Yamaguchi Y, Peeva E, Adiri R, et al. Response to ritlecitinib with or without narrow-band ultraviolet B add-on therapy in patients with active nonsegmental vitiligo: results from a phase 2b extension study. J Am Acad Dermatol. 2025;92(4):781\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2024.11.064.","journal-title":"J Am Acad Dermatol"},{"key":"767_CR64","unstructured":"Pfizer Inc. U.S. FDA approves Pfizer\u2019s XELJANZ\u00ae (tofacitinib) for the treatment of active polyarticular course juvenile idiopathic arthritis. New York (NY): Pfizer; 2020 [cited 2025 Dec 30]. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/us-fda-approves-pfizers-xeljanzr-tofacitinib-treatment."},{"issue":"4","key":"767_CR65","doi-asserted-by":"publisher","first-page":"366","DOI":"10.4103\/ijd.ijd_515_23","volume":"69","author":"A Biswal","year":"2024","unstructured":"Biswal A, Agrawal I, Panda M. Use of oral tofacitinib in the treatment of pediatric vitiligo: a case series. Indian J Dermatol. 2024;69(4):366. https:\/\/doi.org\/10.4103\/ijd.ijd_515_23. (Epub 2024 Aug 19).","journal-title":"Indian J Dermatol"},{"issue":"3","key":"767_CR66","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/jocd.12443","volume":"17","author":"AK Jha","year":"2018","unstructured":"Jha AK, Prasad S, Sinha R. Bimatoprost ophthalmic solution in facial vitiligo. J Cosmet Dermatol. 2018;17(3):437\u201340. https:\/\/doi.org\/10.1111\/jocd.12443.","journal-title":"J Cosmet Dermatol"},{"issue":"2","key":"767_CR67","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.70020","volume":"24","author":"M Ghiasi","year":"2025","unstructured":"Ghiasi M, Isazade A, Marhamati T, Lajevardi V, Shakoei S. The efficacy of 308-nm excimer laser with topical bimatoprost 0.03% for facial vitiligo. J Cosmet Dermatol. 2025;24(2):e70020. https:\/\/doi.org\/10.1111\/jocd.70020.","journal-title":"J Cosmet Dermatol"},{"issue":"5","key":"767_CR68","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/ijd.12631","volume":"54","author":"TS Anbar","year":"2015","unstructured":"Anbar TS, El-Ammawi TS, Abdel-Rahman AT, Hanna MR. The effect of latanoprost on vitiligo: a preliminary comparative study. Int J Dermatol. 2015;54(5):587\u201393. https:\/\/doi.org\/10.1111\/ijd.12631.","journal-title":"Int J Dermatol"},{"issue":"1","key":"767_CR69","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13175","volume":"33","author":"K Nowroozpoor Dailami","year":"2020","unstructured":"Nowroozpoor Dailami K, Hosseini A, Rahmatpour Rokni G, Saeedi M, Morteza-Semnani K, Sadeghi Z, et al. Efficacy of topical latanoprost in the treatment of eyelid vitiligo: a randomized, double-blind clinical trial study. Dermatol Ther. 2020;33(1):e13175. https:\/\/doi.org\/10.1111\/dth.13175.","journal-title":"Dermatol Ther"},{"issue":"4","key":"767_CR70","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/09546634.2019.1658860","volume":"32","author":"SA Eldelee","year":"2021","unstructured":"Eldelee SA, Gheida SF, Sarhan NI, Ibrahim ZA, Elfar NN. Evaluation of the effect of combined intralesional injection of prostaglandin F2\u03b1 with narrow band UVB phototherapy in treatment of resistant cases of vitiligo. J Dermatol Treat. 2021;32(4):383\u201390. https:\/\/doi.org\/10.1080\/09546634.2019.1658860.","journal-title":"J Dermatol Treat"},{"issue":"450","key":"767_CR71","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7710","volume":"10","author":"JM Richmond","year":"2018","unstructured":"Richmond JM, Strassner JP, Zapata L Jr, et al. Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Sci Transl Med. 2018;10(450):eaam7710. https:\/\/doi.org\/10.1126\/scitranslmed.aam7710.","journal-title":"Sci Transl Med"},{"key":"767_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01647-6","volume":"8","author":"ZQ Wang","year":"2023","unstructured":"Wang ZQ, Zhang ZC, Wu YY, et al. Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy. Sig Transduct Target Ther. 2023;8:420. https:\/\/doi.org\/10.1038\/s41392-023-01647-6.","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"767_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s13072-020-00333-z","volume":"13","author":"A Trivedi","year":"2020","unstructured":"Trivedi A, Mehrotra A, Baum CE, Lewis B, Basuroy T, Blomquist T, et al. Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation. Epigenetics Chromatin. 2020;13(1):14. https:\/\/doi.org\/10.1186\/s13072-020-00333-z.","journal-title":"Epigenetics Chromatin"},{"key":"767_CR74","unstructured":"Vyne Therapeutics. VYNE therapeutics announces positive data from phase 1b trial for novel BET inhibitor VYN201 in patients with nonsegmental vitiligo. VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients withNonsegmental Vitiligo - BioSpace."},{"issue":"12","key":"767_CR75","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/exd.12508","volume":"23","author":"J Seneschal","year":"2014","unstructured":"Seneschal J, Boniface K, Ezzedine K, Taieb A. Accelerating bleaching in vitiligo: balancing benefits versus risks. Exp Dermatol. 2014;23(12):879\u201380. https:\/\/doi.org\/10.1111\/exd.12508.","journal-title":"Exp Dermatol"},{"issue":"6","key":"767_CR76","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1111\/bjd.13642","volume":"172","author":"ES Tan","year":"2015","unstructured":"Tan ES, Sarkany R. Topical monobenzyl ether of hydroquinone is an effective and safe treatment for depigmentation of extensive vitiligo in the medium term: a retrospective cohort study of 53 cases. Br J Dermatol. 2015;172(6):1662\u20134. https:\/\/doi.org\/10.1111\/bjd.13642.","journal-title":"Br J Dermatol"},{"issue":"6","key":"767_CR77","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/bjd.12571","volume":"169","author":"L Komen","year":"2013","unstructured":"Komen L, Zwertbroek L, Burger SJ, van der Veen JP, de Rie MA, Wolkerstorfer A. Q-switched laser depigmentation in vitiligo, most effective in active disease. Br J Dermatol. 2013;169(6):1246\u201351. https:\/\/doi.org\/10.1111\/bjd.12571.","journal-title":"Br J Dermatol"},{"issue":"5","key":"767_CR78","first-page":"248","volume":"91","author":"C Grau","year":"2013","unstructured":"Grau C, Silverberg NB. Vitiligo patients seeking depigmentation therapy: a case report and guidelines for psychological screening. Cutis. 2013;91(5):248\u201352.","journal-title":"Cutis"},{"issue":"1","key":"767_CR79","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4103\/0378-6323.90947","volume":"78","author":"Y Gauthier","year":"2012","unstructured":"Gauthier Y, Benzekri L. Non-cultured epidermal suspension in vitiligo: from laboratory to clinic. Indian J Dermatol Venereol Leprol. 2012;78(1):59\u201363. https:\/\/doi.org\/10.4103\/0378-6323.90947.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"767_CR80","doi-asserted-by":"publisher","first-page":"576","DOI":"10.26574\/maedica.2023.18.4.576","volume":"18","author":"M Chandela","year":"2023","unstructured":"Chandela M, Khurana VK, Mehta RK, Saxena AK, Mohanty S, Jethani S. A study of autologous non-cultured epidermal suspension (NCES) transplant in patients with stable vitiligo without the use of NB-UVB. Maedica (Bucur). 2023;18(4):576\u201385. https:\/\/doi.org\/10.26574\/maedica.2023.18.4.576.","journal-title":"Maedica (Bucur)."},{"issue":"3","key":"767_CR81","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1001\/jamadermatol.2020.5756","volume":"157","author":"HJ Ju","year":"2021","unstructured":"Ju HJ, Bae JM, Lee RW, et al. Surgical interventions for patients with vitiligo: a systematic review and meta-analysis. JAMA Dermatol. 2021;157(3):307\u201316. https:\/\/doi.org\/10.1001\/jamadermatol.2020.5756.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"767_CR82","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1111\/bjd.12007","volume":"167","author":"A Budania","year":"2012","unstructured":"Budania A, Parsad D, Kanwar AJ, Dogra S. Comparison between autologous noncultured epidermal cell suspension and suction blister epidermal grafting in stable vitiligo: a randomized study. Br J Dermatol. 2012;167(6):1295\u2013301. https:\/\/doi.org\/10.1111\/bjd.12007.","journal-title":"Br J Dermatol"},{"issue":"6","key":"767_CR83","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1111\/j.1365-2133.2010.10004.x","volume":"163","author":"N van Geel","year":"2010","unstructured":"van Geel N, Wallaeys E, Goh BK, De Mil M, Lambert J. Long-term results of noncultured epidermal cellular grafting in vitiligo, halo naevi, piebaldism and naevus depigmentosus. Br J Dermatol. 2010;163(6):1186\u201393. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.10004.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"767_CR84","doi-asserted-by":"publisher","first-page":"156","DOI":"10.4103\/JCAS.JCAS_61_22","volume":"17","author":"S Choudhary","year":"2024","unstructured":"Choudhary S, Hayatnagarkar S, Kaur M, Patra S. Noncultured epidermal suspension procedure of vitiligo surgery using freeze-dried trypsin coated on silicon pellets. J Cutan Aesthet Surg. 2024;17(2):156\u20137. https:\/\/doi.org\/10.4103\/JCAS.JCAS_61_22.","journal-title":"J Cutan Aesthet Surg"},{"issue":"2","key":"767_CR85","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jaad.2025.03.066","volume":"93","author":"AG Pandya","year":"2025","unstructured":"Pandya AG, Mahmoud BH, Huggins RH, Ganesan AK, Silverberg NB, Munavalli G, et al. Autologous cell harvesting device provides repigmentation and improves quality-of-life for patients with stable vitiligo lesions in a large and diverse patient population. J Am Acad Dermatol. 2025;93(2):378\u201386. https:\/\/doi.org\/10.1016\/j.jaad.2025.03.066.","journal-title":"J Am Acad Dermatol"},{"key":"767_CR86","first-page":"315","volume":"58","author":"SS Das","year":"1992","unstructured":"Das SS, Pasricha JS. Punch grafting as a treatment for residual lesions of vitiligo. Indian J Dermatol Venereol Leprol. 1992;58:315\u20139.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"767_CR87","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jaad.2018.04.039","volume":"79","author":"JM Bae","year":"2018","unstructured":"Bae JM, Kim MH, Kim HS, Lee JH, Kim GM. Motorized 0.8-mm micropunch grafting for refractory vitiligo: a retrospective study of 230 cases. J Am Acad Dermatol. 2018;79(4):720-727.e1. https:\/\/doi.org\/10.1016\/j.jaad.2018.04.039.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"767_CR88","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4103\/0974-2077.112668","volume":"6","author":"I Majid","year":"2013","unstructured":"Majid I. Grafting in vitiligo: how to get better results and how to avoid complications. J Cutan Aesthet Surg. 2013;6(2):83\u20139. https:\/\/doi.org\/10.4103\/0974-2077.112668.","journal-title":"J Cutan Aesthet Surg"},{"issue":"6","key":"767_CR89","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1365-4632.2005.02697.x","volume":"45","author":"K Lahiri","year":"2006","unstructured":"Lahiri K, Malakar S, Sarma N, Banerjee U. Repigmentation of vitiligo with punch grafting and narrow-band UV-B (311 nm)\u2014a prospective study. Int J Dermatol. 2006;45(6):649\u201355. https:\/\/doi.org\/10.1111\/j.1365-4632.2005.02697.x.","journal-title":"Int J Dermatol"},{"issue":"6","key":"767_CR90","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1590\/abd1806-4841.20176332","volume":"92","author":"G Dellatorre","year":"2017","unstructured":"Dellatorre G, Bertolini W, Castro CCS. Optimizing suction blister epidermal graft technique in the surgical treatment of vitiligo. An Bras Dermatol. 2017;92(6):888\u201390. https:\/\/doi.org\/10.1590\/abd1806-4841.20176332.","journal-title":"An Bras Dermatol"},{"issue":"12","key":"767_CR91","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1046\/j.1524-4725.1999.99069.x","volume":"25","author":"S Gupta","year":"1999","unstructured":"Gupta S, Jain VK, Saraswat PK. Suction blister epidermal grafting versus punch skin grafting in recalcitrant and stable vitiligo. Dermatol Surg. 1999;25(12):955\u20138. https:\/\/doi.org\/10.1046\/j.1524-4725.1999.99069.x.","journal-title":"Dermatol Surg"},{"issue":"3","key":"767_CR92","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1524-4725.2006.32078.x","volume":"32","author":"S Nanda","year":"2006","unstructured":"Nanda S, Relhan V, Grover C, Reddy BS. Suction blister epidermal grafting for management of eyelid vitiligo: special considerations. Dermatol Surg. 2006;32(3):387\u201392. https:\/\/doi.org\/10.1111\/j.1524-4725.2006.32078.x.","journal-title":"Dermatol Surg"},{"issue":"2","key":"767_CR93","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1524-4725.2007.34034.x","volume":"34","author":"A Babu","year":"2008","unstructured":"Babu A, Thappa DM, Jaisankar TJ. Punch grafting versus suction blister epidermal grafting in the treatment of stable lip vitiligo. Dermatol Surg. 2008;34(2):166\u201378. https:\/\/doi.org\/10.1111\/j.1524-4725.2007.34034.x.","journal-title":"Dermatol Surg"},{"issue":"1","key":"767_CR94","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1067\/mjd.2003.415","volume":"49","author":"S Gupta","year":"2003","unstructured":"Gupta S, Kumar B. Epidermal grafting in vitiligo: influence of age, site of lesion, and type of disease on outcome. J Am Acad Dermatol. 2003;49(1):99\u2013104. https:\/\/doi.org\/10.1067\/mjd.2003.415.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"767_CR95","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2147\/CCID.S151503","volume":"26","author":"D Bassiouny","year":"2018","unstructured":"Bassiouny D, Esmat S. Autologous non-cultured melanocyte-keratinocyte transplantation in the treatment of vitiligo: patient selection and perspectives. Clin Cosmet Investig Dermatol. 2018;26(11):521\u201340. https:\/\/doi.org\/10.2147\/CCID.S151503.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"767_CR96","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.det.2016.11.009","volume":"35","author":"T Mohammad","year":"2017","unstructured":"Mohammad T, Hamzavi I. Surgical therapies for vitiligo. Dermatol Clin. 2017;35:193\u2013203.","journal-title":"Dermatol Clin"},{"issue":"4","key":"767_CR97","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/ijd.14286","volume":"58","author":"N Parambath","year":"2019","unstructured":"Parambath N, Sharma VK, Parihar AS, Sahni K, Gupta S. Use of platelet-rich plasma to suspend noncultured epidermal cell suspension improves repigmentation after autologous transplantation in stable vitiligo: a double-blind randomized controlled trial. Int J Dermatol. 2019;58(4):472\u20136. https:\/\/doi.org\/10.1111\/ijd.14286.","journal-title":"Int J Dermatol"},{"key":"767_CR98","first-page":"S37","volume":"74 Suppl","author":"D Parsad","year":"2008","unstructured":"Parsad D, Gupta S, IADVL Dermatosurgery Task Force. Standard guidelines of care for vitiligo surgery. Indian J Dermatol Venereol Leprol. 2008;74 Suppl:S37-45.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"12","key":"767_CR99","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1001\/archderm.134.12.1543","volume":"134","author":"MD Njoo","year":"1998","unstructured":"Njoo MD, Westerhof W, Bos JD, Bossuyt PM. A systematic review of autologous transplantation methods in vitiligo. Arch Dermatol. 1998;134(12):1543\u20139. https:\/\/doi.org\/10.1001\/archderm.134.12.1543.","journal-title":"Arch Dermatol"},{"issue":"3","key":"767_CR100","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/ced.14196","volume":"46","author":"I Ucuz","year":"2021","unstructured":"Ucuz I, Altunisik N, Sener S, Turkmen D, Kavuran NA, Marsak M, et al. Quality of life, emotion dysregulation, attention deficit and psychiatric comorbidity in children and adolescents with vitiligo. Clin Exp Dermatol. 2021;46(3):510\u20135. https:\/\/doi.org\/10.1111\/ced.14196.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"767_CR101","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","volume":"22","author":"K Ezzedine","year":"2021","unstructured":"Ezzedine K, Eleftheriadou V, Jones H, et al. Psychosocial effects of vitiligo: a systematic literature review. Am J Clin Dermatol. 2021;22(6):757\u201374. https:\/\/doi.org\/10.1007\/s40257-021-00631-6.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"767_CR102","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.18129","volume":"36","author":"M Picardo","year":"2022","unstructured":"Picardo M, Huggins RH, Jones H, Marino R, Ogunsola M, Seneschal J. The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes. J Eur Acad Dermatol Venereol. 2022;36(9):1507\u201323. https:\/\/doi.org\/10.1111\/jdv.18129.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"767_CR103","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jamadermatol.2024.0594","volume":"160","author":"AS Paller","year":"2024","unstructured":"Paller AS, Rangel SM, Chamlin SL, et al. Stigmatization and mental health impact of chronic pediatric skin disorders. JAMA Dermatol. 2024;160(6):621\u201330. https:\/\/doi.org\/10.1001\/jamadermatol.2024.0594.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"767_CR104","doi-asserted-by":"publisher","first-page":"108","DOI":"10.5455\/msm.2020.32.108-111","volume":"32","author":"MA Alharbi","year":"2020","unstructured":"Alharbi MA. Identifying patients at higher risk of depression among patients with vitiligo at outpatient setting. Mater Sociomed. 2020;32(2):108\u201311. https:\/\/doi.org\/10.5455\/msm.2020.32.108-111.","journal-title":"Mater Sociomed"},{"issue":"10","key":"767_CR105","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","volume":"159","author":"K Bibeau","year":"2023","unstructured":"Bibeau K, Ezzedine K, Harris JE, et al. Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study. JAMA Dermatol. 2023;159(10):1124\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2023.2787.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"767_CR106","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jid.2022.10.021","volume":"143","author":"JH Lee","year":"2023","unstructured":"Lee JH, Ju HJ, Seo JM, Almurayshid A, Kim GM, Ezzedine K, et al. Comorbidities in patients with vitiligo: a systematic review and meta-analysis. J Invest Dermatol. 2023;143(5):777-789.e6. https:\/\/doi.org\/10.1016\/j.jid.2022.10.021.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"767_CR107","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40257-013-0037-5","volume":"14","author":"GA Bin Saif","year":"2013","unstructured":"Bin Saif GA, Al-Balbeesi AO, Binshabaib R, Alsaad D, Kwatra SG, Alzolibani AA, et al. Quality of life in family members of vitiligo patients: a questionnaire study in Saudi Arabia. Am J Clin Dermatol. 2013;14(6):489\u201395. https:\/\/doi.org\/10.1007\/s40257-013-0037-5.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"767_CR108","doi-asserted-by":"publisher","first-page":"32","DOI":"10.25259\/IJDVL_928_20","volume":"88","author":"S Agrawal","year":"2021","unstructured":"Agrawal S, Satapathy S, Gupta V, Sreenivas V, Khaitan BK, Ramam M. Family vitiligo impact scale: a scale to measure the quality-of-life of family members of patients with vitiligo. Indian J Dermatol Venereol Leprol. 2021;88(1):32\u20139. https:\/\/doi.org\/10.25259\/IJDVL_928_20.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"9 Suppl 1","key":"767_CR109","first-page":"S19","volume":"14","author":"D Datta","year":"2021","unstructured":"Datta D, Sarkar R, Podder I. Parental stress and quality of life in chronic childhood dermatoses: a review. J Clin Aesthet Dermatol. 2021;14(9 Suppl 1):S19\u201323.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"4","key":"767_CR110","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/00008475","volume":"210","author":"K Ongenae","year":"2005","unstructured":"Ongenae K, Dierckxsens L, Brochez L, van Geel N, Naeyaert JM. Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage. Dermatology. 2005;210(4):279\u201385. https:\/\/doi.org\/10.1159\/00008475.","journal-title":"Dermatology"},{"issue":"1","key":"767_CR111","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/ijd.70101","volume":"65","author":"HW Lim","year":"2026","unstructured":"Lim HW, Zhang C, Taylor M, Dlova NC, Concei\u00e7\u00e3o K, Jablonski N, et al. International expert consensus on knowledge gaps in care for dermatologic disorders in skin of color. Int J Dermatol. 2026;65(1):41\u201356. https:\/\/doi.org\/10.1111\/ijd.70101.","journal-title":"Int J Dermatol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00767-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00767-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00767-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:16:54Z","timestamp":1790680614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-026-00767-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":111,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["767"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00767-0","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jade Howard MD, William Fitzmaurice MD, Aleena Boby BA and Benjamin Levin BA have no conflicts to declare. Nanette Silverberg MD MPH is an investigator for Incyte and Avita, and has advised or spoken for Abbvie, Incyte, Pelthos, Pfizer, Regeneron, Sanofi, and Verrica.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable to this article, no datasets were generated or analyzed during the current study.","order":2,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, no human subjects were involved.","order":3,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, no human subjects were involved.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, no identifiable patient data or photos are included in the study.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JH, WF, and NBS all contributed equally to the initial versions of the manuscript. AB and BL revised the penultimate version and NBS revised the final version. All authors have read and approved the final version of the manuscript and agree to be accountable for the work.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}